EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 11 (2025) SICOT-J, 11 (2025) 16 References
Open Access
Issue
SICOT-J
Volume 11, 2025
Article Number 16
Number of page(s) 8
Section Lower Limb
DOI https://doi.org/10.1051/sicotj/2025011
Published online 13 March 2025
  1. Inwards CY, Bloem JL, Hogendoorn PCW (2020) Dedifferentiated chondrosarcoma. In: WHO Classification of Tumours. The WHO Classification of Tumours Editorial Board. 5th edn: Soft Tissue and Bone, Editor. Lyon, International Arctic Research Center. [Google Scholar]
  2. Ogura K, Higashi T, Kawai A (2017) Statistics of bone sarcoma in Japan: Report from the bone and soft tissue Tumor Registry in Japan. J Orthop Sci 22, 133–143. [CrossRef] [PubMed] [Google Scholar]
  3. Amary MF, Bacsi K, Maggiani F, et al. (2011) IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224, 334–343. [CrossRef] [PubMed] [Google Scholar]
  4. Staals EL, Bacchini P, Bertoni F (2006) Dedifferentiated central chondrosarcoma. Cancer 106, 2682–2691. [CrossRef] [PubMed] [Google Scholar]
  5. Staals EL, Bacchini P, Mercuri M, Bertoni F (2007) Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. J Bone Joint Surg Am 89, 987–993. [CrossRef] [PubMed] [Google Scholar]
  6. Grimer RJ, Gosheger G, Taminiau A, et al. (2007) Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer 43, 2060–2065. [CrossRef] [PubMed] [Google Scholar]
  7. Miao R, Choy E, Raskin KA, et al. Prognostic factors in dedifferentiated chondrosarcoma: a retrospective analysis of a large series treated at a single institution. Sarcoma 2019, 9069272. [PubMed] [Google Scholar]
  8. Strotman PK, Reif TJ, Kliethermes SA, et al. (2017) Dedifferentiated chondrosarcoma: A survival analysis of 159 cases from the SEER database (2001–2011). J Surg Oncol 116, 252–257. [CrossRef] [PubMed] [Google Scholar]
  9. Kawaguchi S, Sun T, Lin PP, et al. (2014) Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? Clin Orthop Relat Res 472, 983–989. [CrossRef] [PubMed] [Google Scholar]
  10. Nemecek E, Funovics PT, Hobusch GM, et al. (2018) C-reactive protein: an independent predictor for dedifferentiated chondrosarcoma. J Orthop Res 36, 2797–2801. [CrossRef] [PubMed] [Google Scholar]
  11. Sambri A, Tuzzato G, Donati DM, et al. (2021) Pathological fracture does not affect prognosis in dedifferentiated chondrosarcoma of the limbs. J Orthop Sci 26, 473–477. [CrossRef] [PubMed] [Google Scholar]
  12. Gonzalez MR, Bryce-Alberti M, Portmann-Baracco A, et al. (2022) Appendicular dedifferentiated chondrosarcoma: a management and survival study from the SEER database. J Bone Oncol 37, 100456. [CrossRef] [PubMed] [Google Scholar]
  13. Hompland I, Ferrari S, Bielack S, et al. (2021) Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: results from the EUROpean Bone Over 40 Sarcoma Study. Eur J Cancer 151, 150–158. [CrossRef] [PubMed] [Google Scholar]
  14. Biermann JS, Chow W, Reed DR, et al. (2017) NCCN Guidelines Insights: Bone Cancer, Version 2.2017. J Natl Compr Canc Netw 15, 155–167. [CrossRef] [PubMed] [Google Scholar]
  15. Strauss SJ, Frezza AM, Abecassis N, et al. (2021) Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 32(12), 1520–1536. [CrossRef] [PubMed] [Google Scholar]
  16. Gao Z, Lu T, Song H, et al. (2019) Prognostic factors and treatment options for patients with high-grade chondrosarcoma. Med Sci Monit 25, 8952–8967. [CrossRef] [PubMed] [Google Scholar]
  17. Wittekind C, Compton C, Quirke P, et al. (2009) A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status. Cancer 115, 3483–3488. [CrossRef] [PubMed] [Google Scholar]
  18. Goda JS, Ferguson PC, O’Sullivan B, et al. (2011) High-risk extracranial chondrosarcoma: long-term results of surgery and radiation therapy. Cancer 117, 2513–2519. [CrossRef] [PubMed] [Google Scholar]
  19. Tanaka K, Ozaki T (2019) New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin Oncol 49, 103–107. [CrossRef] [PubMed] [Google Scholar]
  20. Italiano A, Mir O, Cioffi A, et al. (2013) Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol 24, 2916–2922. [CrossRef] [PubMed] [Google Scholar]
  21. Link MP, Goorin AM, Miser AW, et al. (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314, 1600–1606. [CrossRef] [PubMed] [Google Scholar]
  22. Tsukamoto S, Mavrogenis AF, Nitta Y, et al. (2024) A systematic review of adjuvant chemotherapy in localized dedifferentiated chondrosarcoma. Curr Oncol 31, 566–578. [CrossRef] [PubMed] [Google Scholar]
  23. Lee FY, Mankin HJ, Fondren G, et al. (1999) Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 81, 326–338. [CrossRef] [PubMed] [Google Scholar]
  24. Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. (2008) The clinical approach towards chondrosarcoma. Oncologist 13, 320–329. [CrossRef] [PubMed] [Google Scholar]
  25. Mercado CE, Holtzman AL, Rotondo R, et al. (2019) Proton therapy for skull base tumors: A review of clinical outcomes for chordomas and chondrosarcomas. Head Neck 41, 536–541. [CrossRef] [PubMed] [Google Scholar]
  26. Nakamura T, Sugaya J, Naka N, et al. (2020) Standard treatment remains the recommended approach for patients with bone sarcoma who underwent unplanned surgery: report from the Japanese Musculoskeletal Oncology Group, Cancer Manag Res 12, 10017–10022. [CrossRef] [Google Scholar]
  27. Bielack SS, Smeland S, Whelan JS, et al. (2015) Methotrexate, Doxorubicin, and Cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 Good Response Randomized Controlled Trial, J Clin Oncol 33, 2279–2287. [CrossRef] [PubMed] [Google Scholar]
  28. Albergo JI, Gaston CL, Jeys LM, et al. (2015) Management and prognostic significance of pathological fractures through chondrosarcoma of the femur. Int Orthop 39, 943–946. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.